This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

United Therapeutics Gets Approvable Letter for Remodulin

Updated from 9:21 a.m. EST

Shares of United Therapeutics (UTHR - Get Report) jumped 23% Monday after the biotech company received an "approvable letter" from the Food and Drug Administration for its drug Remodulin to treat pulmonary arterial hypertension. The biotech firm said final approval is contingent on discussions with the FDA over the drug's labeling. The regulatory agency will also require United Therapeutics to conduct a post-approval study of Remodulin to verify its clinical benefit.

United Therapeutics was up $2.15, or 23%, to $11.50 in recent Monday trading.

Pulmonary arterial hypertension is a disease in which elevated blood pressure in the lungs causes shortness of breath and heart damage. About 50,000 people in North America and Europe suffer from various forms of the life-threatening disease, according to the company.

Remodulin is administered by injection, and will likely be used by doctors on patients who don't respond or fail oral treatments for the disease. One of these oral drugs is Tracleer, from Swiss biotech firm Actelion, which received FDA approval in November.

While not considered a first-line treatment for pulmonary arterial hypertension, Remodulin could still rack up $100 million in annual sales if it can grab about 5% of the patients suffering from the disease, according to one hedge fund manager, who's long United Therapeutics.

GlaxoSmithKline (GSK - Get Report) also markets an injectable drug, Flolan, for the disease, but the drug must be given to patients directly into a vein. Remodulin, by comparison, is administered by a subcutaneous injection.

On a conference call with analysts Monday morning, United Therapeutics executives say they hope to have all remaining FDA issues with Remodulin cleared up in time to get the drug approved and on the market by the end of the second quarter.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $42.91 0.00%
UTHR $105.20 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs